Incyte Stock: Shares Have Taken a Beating in 2018 – Here’s Why

Following early-stage results that impressed, optimism that Incyte Corp.’s (NASDAQ: INCY) IDO-inhibitor could reshape how we treat cancer surged higher. Unfortunately, that wasn’t the case. The company reported results earlier this year for the use of it in melanoma patients that were so disappointing that it resulted in a near abandoning of IDO-inhibitors not only at Incyte, but at its competitors too.

In this clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss what lessons investors can learn from Incyte’s discouraging failure.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
Or, follow our Google+ page:

Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: